Millenium Biologix Completes Reverse Takeover of Cytovax Biotechnologies

On December 3, 2004, Millenium Biologix Inc. (MBI) completed a reverse takeover of Cytovax Biotechnologies Inc. pursuant to which former shareholders of MBI received common shares of Cytovax. Cytovax has been renamed Millenium Biologix Corp. and operates as a biomedical company focused on the development and commercialization of next generation orthobiologic and skeletal tissue regeneration products that promote the repair and natural healing of human bone and other tissues.
Immediately prior to the amalgamation, MBI completed a private placement for aggregate proceeds of $15 million. RBC Dominion Securities Inc. acted as lead agent in the private placement, with Dlouhy Merchant Group Inc. as co-agent.
MBI was represented by a team from McMillan Binch LLP that included John Craig, Margaret McNee, Pollyanna Lord, Laura Stoddard, Cindy Wan and Sarah Redekopp.
Cytovax was represented by Dwight I. Bliss, Michael Gluckman, Colleen Cebuliak, Dana Bissoondatt and Marlon Rajakaruna of Fraser Milner Casgrain LLP in Edmonton.
Wildeboer Dellelce LLP was counsel to the agents with a team that included Troy Pocaluyko, Al Wiens and Sanjeev Patel.